medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21265993; this version posted November 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

## 1 Responsivity of the striatal dopamine system to methylphenidate – a

2 within-subject I-123-ß-CIT-SPECT study in children and adolescents

## 3 with Attention-Deficit/Hyperactivity Disorder

4 Hans-Christoph Aster<sup>1,2\*</sup>, Marcel Romanos<sup>1</sup>, Susanne Walitza<sup>3</sup>, Manfred Gerlach<sup>1</sup>, Andreas

- 5 Mühlberger<sup>4</sup>, Natalie Hasenauer<sup>5</sup>, Philipp E. Hartrampf<sup>5</sup>, Kai Nerlich<sup>5</sup>, Christoph Reiners<sup>5</sup>,
- 6 Reinhard Lorenz<sup>5</sup>, Andreas K. Buck<sup>5</sup>, Lorenz Deserno<sup>1,6,7\*</sup>
- <sup>1</sup> Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University of
   Würzburg, Germany;
- <sup>9</sup> <sup>2</sup> Department of Neurology, University of Würzburg, Germany
- <sup>3</sup>Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of
   Psychiatry, University of Zürich, Switzerland
- <sup>4</sup>Department of Psychology, Clinical Psychology and Psychotherapy, University of Regensburg,
   Germany;
- <sup>5</sup> Department of Nuclear Medicine, University of Würzburg, Germany;
- <sup>6</sup> Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany;
- <sup>7</sup> Department of Psychiatry and Psychotherapy, Technische Universität Dresden, Germany
- 17
- 18 \*Corresponding authors:
- 19 Lorenz Deserno, MD; Hans-Christoph Aster, MD
- 20 Klinik für Kinder- und Jungendpsychiatrie, Psychotherapie und Psychosomatik
- 21 Universitätsklinikum Würzburg
- 22 Margarete-Höppel Platz 1, 97080 Würzburg
- 23 Email: Deserno\_L@ukw.de; Aster\_H@ukw.de
- 24
- 25 Length of Manuscript: 12 pages, 4606 words.

# **CIT-SPECT** study in adolescent males with ADHD

#### 27 Abstract

28 Background: Methylphenidate (MPH) is the first-line pharmacological treatment of attention-

29 deficit/hyperactivity disorder (ADHD). MPH binds to the dopamine (DA) transporter (DAT), which 30 has high density in the striatum. Assessments of the striatal dopamine transporter by single positron

emission computed tomography (SPECT) in childhood and adolescent patients are rare but can provide 31

32 insight in how effects of MPH affect DAT availability. The aim of our within-subject study was to

33 investigate the effect of MPH on DAT availability and how responsivity to MPH in DAT availability

- 34 is linked to clinical symptoms and cognitive functioning.
- 35 Methods: Thirteen adolescent male patients (9-16 years) with diagnosis of ADHD according to DSM-

IV and long-term stimulant medication (for at least 6 months) with MPH were assessed twice within 7 36

37 days using SPECT after application of I-123-B-CIT to examine DAT binding potential (DAT BP). 38 SPECT measures took place in on and off-MPH status balanced for order across participants. A virtual-

39 reality continuous-performance test was performed at each time point. Further clinical symptoms were

40 assessed for baseline off-MPH.

41 Results: On-MPH status was associated with a highly significant decrease (-27,6%) of striatal DAT BP

42 as compared to off-MPH (t=4.93, p<0.001). More pronounced decrease in striatal DAT BP was

43 associated with higher off-MPH attentional and externalizing symptom ratings (Pearson r=0.68,

p=0.01). Striatal DAT BP off-MPH, but not on- MPH, was associated with higher symptom ratings 44

45 off-MPH (Pearson r=0.56, p=0.04). In further exploratory analysis in left vs. right striatal sub-regions,

46 stronger decrease in DAT BP in the right caudate nucleus was weakly associated with improved

47 performance in the continuous-performance test (Pearson r = -0.54, p = 0.07).

48 Conclusion: Our findings corroborate previous reports from mainly adult samples that MPH reduces

49 striatal DAT BP availability and suggest higher off-MPH DAT BP, likely reflecting low baseline DA

levels, as a marker of symptom severity. More speculatively, regional specific responsivity of DAT BP 50

to MPH may reflect treatment response with respect to cognitive functioning. However, implications 51

from this small patient sample should be treated with caution and warrant replication. 52

# **CIT-SPECT** study in adolescent males with ADHD

#### Introduction 54

55 Attention-deficit/hyperactivity disorder (ADHD) is a common child and adolescent psychiatric 56 disorder associated with substantial psychosocial impairment on the individual and family level (1).

57 ADHD significantly impacts on mental health and the social services (1). The clinical phenotype is

58 characterized by motor hyperactivity, increased impulsivity and impaired attention starting in the most

59 cases in childhood. There is a relevant increase of comorbid symptoms and disorders, for example

60 social oppositional and conduct problems, substance use and depression (2). Clinically relevant ADHD

61 symptoms persist into adulthood to a large extent (3).

62 Pharmacological interventions by stimulant medication, such as methylphenidate (MPH), are effective 63 and save (4). MPH binds primarily to the dopamine and to some extent to noradrenaline transporter 64 and because of the high density of the dopamine transporter (DAT) in the striatum, striatal DAT is one of MPH's main neurochemical targets (5) and may thus be related to MPH treatment response. 65 Considering different response criteria the response to MPH is limited to approx. 70% of childhood 66 67 patients (6), the identification of the neurobiological correlates (or even determinants) may allow to establish quantitative markers of treatment response in the long run to provide more individualized 68 69 outcome predictions in the future. Therefore, the investigation of the striatal dopamine system by 70 means of Single-Positron-Emission-Computed Tomography (SPECT) and Positron Emission 71 Tomography (PET), and in particular its modulation by stimulant medication in an children's and 72 adolescents population, may provide a better understanding of whether MPH-related changes in DAT

73 availability are indeed related to changes in clinical symptoms.

74 Numerous functional magnetic resonance imaging (fMRI) and Electroencephalography (EEG) studies have been published on altered neurocognitive processes in fronto-striatal brain circuits of ADHD 75 76 patients for example during executive function (7, 8), Studies approaching the striatal dopaminergic 77 system by SPECT or PET are clearly more challenging to conduct, especially in an children's and 78 adolescents population. However, molecular imaging techniques can provide insights to neurochemical 79 targets of a drug (9). Due to the ethical limitations and high costs of neurochemical imaging studies 80 with radioactive ligands, only few studies with relatively small numbers of patients were published 81 until now (10). These studies are highly heterogeneous in regard to sample characteristics as well as 82 the applied tracers rendering direct comparisons considerably difficult, especially when results are 83 conflicting. Nonetheless, DAT has been studied most consistently as summarized in a meta-analysis 84 of 9 PET and SPECT studies in adult patients (10). Adult patients with ADHD had a higher striatal 85 DAT availability (likely indicating lower striatal DA levels (11)). However, the study showed that 86 about half of the variability in DAT availability was related to medication status. Patients who were 87 already treated with psychostimulants, such as MPH, showed a significantly higher DAT availability 88 than groups of patients who were drug-naïve (10). This was discussed as an adaptive response to the 89 long-term blockade of dopamine transporters by continuous treatment. This could in turn explain the 90 partial decrease in long-term efficacy of MPH at the same dose. However, only cross-sectional studies 91 were included (10), which limits conclusions in this regard. A longitudinal study, however, confirmed 92 that one year treatment on MPH in adult ADHD lead to enhanced DAT availability (12). Nonetheless, 93 when using a tracer that binds to D2 receptor to measures displacement by one-year MPH treatment as 94 marker of DA levels in adult ADHD, it was found that MPH treatment lead to elevated DA levels (13). 95 This increase in DA levels (measured via D2 receptor displacement) was correlated with improved 96 inattention symptoms after one-year MPH (13).

97 Although the dopaminergic system undergoes substantial development changes (14, 15), to our 98 knowledge only two studies investigating the effect of MPH therapy on DAT have been published in

### Responsivity of the striatal dopamine system to methylphenidate – a within-subject I-123-B-CIT-SPECT study in adolescent males with ADHD

99 adolescent ADHD. Results from both studies indicate that MPH treatment leads to a decrease in DAT

100 availability in response to MPH treatment (16). However, only one of the two studies found a relation 101 to clinical symptoms based on a subgroup analysis. Neither study reported on relationships with

neurocognitive performance measures. To fill this gap, we here detail a 123- $\beta$ -CIT SPECT study on

103 13 male children and adolescents with ADHD, who were on continuous medication (for at least 6

104 months) on MPH before study enrollment. All patients performed two SPECT measurements (counter-

balanced for order), one on MPH, and another one after 7 days of treatment cessation (off-MPH).

106 Binding of 123-B-CIT is aiming at quantifying DAT density 24h after injection. We concomitantly

107 applied both clinical rating scales as well as neurocognitive testing procedures in a virtual reality setting

108 in order to determine whether DAT density was correlated to measures of ADHD symptoms and

- 109 cognitive performance.
- 110

### 111 Methods

Study design. All participants were on continuous MPH medication for at least 6 months prior to 112 113 inclusion in the study. During this period, MPH was taken once a day between 7 and 8 a.m. by oral 114 administration. Patients received daily doses of MPH between 0.4 and 1.2 mg/kg body weight. Those 115 dosage regimes were met individually based on clinical needs and prescribed by the respective treating 116 child and adolescent psychiatrists. All participants received long-acting MPH preparations (Medikinet 117 retard® or Concerta®) ensuring continuous efficacy of the treatment during the lengthy procedures of 118 the study. The cessation phases required for participation were organized to comply with clinical 119 demands such as regular drug holidays or yearly cessation to determine further necessity of the drug. 120 In all patients, treatment was reintroduced after study participations based on the families and the 121 physicians estimate that medication provided significant benefit. The study procedure was 122 accomplished on four days. Day A and B were two consecutive days as were day C and D with one 123 week in between. Investigations on day A and B were performed on MPH, on day C and D off-MPH. 124 To counter-balance for order effects, 9 patients were investigated first on MPH, and then again after 7 125 days of cessation while 4 patients initially stopped medication for 7 days before the first SPECT 126 measurement and were assessed a second time after 7 days of MPH treatment. Study compliance was 127 assessed by self- and mother's report.

128 Sample. The study was approved by the Federal Office for Radiation Protection ("Bundesamt für 129 Strahlenschutz") and the ethics committee of the University of Wuerzburg and was performed in 130 accordance with the ethical standards laid down in the latest version of the Declaration of Helsinki. 13 131 male children and adolescent patients with diagnosis of ADHD according to DSM-IV and aged 9-16 132 years (mean  $\pm$  S.D.: 11.3  $\pm$  2.8) were recruited in the outpatient clinic of the Department of Child and 133 Adolescent Psychiatry, Psychosomatics and Psychotherapy of the University of Wuerzburg. All 134 patients and their legal guardians gave written informed consent before inclusion in the study. All 135 participants were thoroughly assessed by complete semi-structured interview (Kiddie-Sads-PL, 136 German version) determining ADHD status and comorbid disorders. Parents filled in the Child behavior Checklist and the "Depressions inventar für Kinder- und Jugendliche" determining depressive 137 138 symptoms. Exclusion criteria were female, sex, history of birth complication, traumatic head injury, 139 seizures, severe somatic or neurological disorders, psychosis, autism spectrum disorder, severe conduct 140 disorder, and IQ below 85. All patients had received continuous pharmacological treatment with MPH 141 for at least 6 months before inclusion in the study (see Table 1 for sample characteristics).

Single Photon Emission Computed Tomography. To assess the DAT availability and binding potential,
 respectively, the highly affine presynaptic dopamine transporter ligand, Iodine-123-β-CIT [2-β-

### Responsivity of the striatal dopamine system to methylphenidate – a within-subject I-123-ß-CIT-SPECT study in adolescent males with ADHD

- 144 carboxy-methoxy- $3-\beta$ -(4-iodophenyl)-tropane] was used (17, 18). Image acquisition was performed on
- 145 Day B and D 24 h after i.v. injection of weight-adapted activity of Iodine-123- $\beta$ -CIT on Day A and C 146 (19) with a dual-head gamma camera (E.cam duet; Siemens) fitted with middle-energy, parallel-hole
- 146 (19) with a dual-nead gamma camera (E.cam duet; Siemens) fitted with middle-energy, parallel-hole 147 collimators. Energy window for iodine-123 was set on 160 keV +/- 15%. For each scan, 60 projections
- (40s per frame) were collected in step-and-shoot mode on a circular orbit. The image data were
- reconstructed by standard filtered back projection using Butterworth filter with cut-off frequency of
- 150 0,6/cm and order 8, followed by attenuation correction using a first-order method (20). To block
- 151 binding of free iodine in the thyroid gland, the patients took 16,4mg/kgKG sodium perchlorate (Irenat)
- 152 orally 20 minutes before injection of I-123- $\beta$ -CIT, followed by 6mg/kgKG Irenat three times a day the
  - 153 following three days. For evaluation (intra-individual comparison of the influence of methylphenidate 154 treatment) and standardized quantification by stereotactic normalization patient studies were co-
  - registered with a normal template of a healthy age matched control subject. Standardized templates (in size and shape) created in our normal template (based on Colin 27 NMR-Brain (21)) were used for
  - defining the striatal regions of interest. After transforming the region of interests (ROI) templates for
  - 158 the striatum and its subregions as well as for the reference region in the occipital lobe from the normal
  - template onto the two SPECT/CT patient studies of interest (on/off MPH), the position of the ROI templates were manually adjusted to fit individuals because of anatomical differences (Figure 1). We evaluated the data derived from three consecutive transverse slices, which showed the highest tracer accumulation in the basal ganglia. For semi-quantitative evaluation, DAT availability was calculated using the binding potential (22) ratios [(STR-BKG)/BKG] in the striatum (STR) and its subregions
- 163 using the binding potential (22) ratios [(STR-BKG)/BKG] in the striatum (STR) and its subregions 164 (putamen, caudate nucleus) with an occipital reference region used as background (BKG), as
- 165 recommended by EANM Guidelines (23) and already implemented in this way in other previous
  - 166 studies (24).
- 167



- 168
- Figure 1: MRI with ROI-template-set covering the striatum with caudate nucleus and putamen and an
   occipital background ROI (left); I-123-β-CIT-SPECT (summation of the three consecutive slices with
   the highest tracer uptake in the basal ganglia (right))
- 172 Continuous performance test in virtual reality classroom. On Day A and Day C, patients performed a
- 173 neurocognitive testing procedure in a Virtual Reality Classroom (VRC) (25, 26) thus assessing the
- 174 participants' attention in a more ecological valid setting. Within the VRC, a continuous performance
- test (CPT) was presented on a blackboard while distracting visual (e.g., another teacher coming into
- the room) and auditory (e.g., coughing classmate) stimuli appear. Participants' head movements were
- 177 measured. The VR environment and instructions were presented with a Z800 3D Visor head-mounted
- display (HMD; eMagin, Hopewell Junction, USA) and a closed headphone (Sennheiser, Wedemark,

# **CIT-SPECT** study in adolescent males with ADHD

- 179 Germany), both connected to a notebook with Microsoft Windows operating system. The head position
- 180 was monitored by an electromagnetic tracking device (Minuteman, Polhemus Corporation, Colchester,
- 181 USA) in order to adapt the field of view to head movements and to assess head orientation.

182 The experimenter explained the VRC equipment, made sure the child's eyesight, hearing and cognitive 183 capabilities were unimpaired and adjusted the HMD to the child's head, so that the interior of the virtual classroom could be seen. The child then was instructed to look around in the room to adapt to the 184 185 virtual environment. The child was then given the first task (warm-up task) by the virtual teacher. It 186 was instructed to view a series of numbers appearing on the blackboard and to hit the button of the responding device every time the number "5" preceded by the number "9" occurred. Each of the 187 188 numbers remained on the blackboard for 200 milliseconds (ms) followed by an interstimulus interval 189 of 800 ms. Altogether twenty number stimuli were presented containing five target sequences. If 190 necessary instructions and warm-up trial were repeated. In case the task was completed without making 191 more than one error, the second task (main task) started after a short break.

192 In the main task the participant was instructed by a virtual teacher to view a series of letters presented 193 on the blackboard. The participant had to press the response button as quickly as possible every time he detected the letter "K" preceded by the letter "A". Altogether two blocks of each 680 letter stimuli 194 195 including 72 target stimuli were presented with a stimulus duration of 200 ms and an interstimulus 196 interval of 800 ms. The first block included no distracters. Directly after the first block a second block 197 including the same stimuli and target number was presented. This block included pure auditory (typical 198 classroom sounds like whispering, dropping pencils, etc.), pure visual (paper plane flying across the 199 room) or mixed auditory/visual (bus noisefully driving by outside left window) distracters distributed 200 over the whole block. Each block lasted 11 minutes and 20 seconds.

201 Child Behavior Checklist (CBCL). The CBCL in the version for children and adolescents aged 4-18 202 years captures parents' assessments of their children's competencies and problems. The evaluation of 203 this questionnaire includes the following scales and scores: 3 competency scales (activity, social skills, 204 cross-assessment syndromes (Social Withdrawal, and school). 8 Physical Discomfort, 205 Anxiety/Depressive, Social Problems, Schizoid/Compulsive, Attention Deficit Disorder, Dissocial 206 Behavior, Aggressive Behavior) where comparison is possible across parent, teacher, and self-report 207 forms of this questionnaire system. Scales of internalizing and externalizing behavior and an overall 208 problem behavior score are formed from the syndrome scales (27, 28). The questionnaire was 209 completed by the patients' parents at the time off-MPH.

210 Statistical Analysis. The statistical analyses were conducted using the JASP Toolbox (JASP Team 211 (2020, Version 0.14.1). Specific DAT binding of the patients on and off-MPH 24h after administration 212 of 123-B-CIT was compared using a generalized linear mixed effects model with medication status as 213 fixed effect and individual subjects and medication order as random effects (striatal binding potential 214 ~ medication status + (1|participant) + (1|order). Change scores in regional binding potential and 215 performance in the CPT were calculated by the difference of the respective values at the time of off 216 medication minus on medication. The influence of MPH on the performance in the virtual classroom 217 setting was also analyzed using a generalized linear mixed effects model (correct choices ~ medication 218 status + (1|participant) + (1|order). For correlations, after testing for a normal distribution using the 219 Shapiro-Wilk test, we used Pearson correlation coefficients. All variables were z-scored before 220 analysis. Comparison of correlation coefficients, when indicated, were calculated by a Fisher's z-221 transformation (29).

**CIT-SPECT** study in adolescent males with ADHD

#### 223 **Results**

224 For a sample description, see Table 1.

225 Single Photon Emission Computed Tomography. In a linear mixed effects model with the individual 226 participants as random effects, there was a significant difference in striatal binding potential (BP) 227 between the on and off-MPH DAT BP (degrees of freedom: 20.6, t-value: 4.93, p-value < 0.001, beta 228 estimate: -2.68 (SD: 0.54), see Figure 2 and 3). The medium reduction of DAT binding potential was 229 27,6 % (median 32.1%), ranging from -7.4% to 68.9% (SD: 19.4%). Nominal reductions in the 230 medication condition vs. the non-medication condition were found in all participants except for one, 231 who showed basically no change in DAT and a second participant, who displayed a nominal increase 232 of DAT.



235

**CIT-SPECT** study in adolescent males with ADHD



236 Figure 3: DAT-scans on and off-MPH in a single subject. Acquisition time points were 24h after tracer 237 application. Color sale is hot metal. Time span between the two images was seven days. On the right

238 side a decrease of tracer accumulation in the basal ganglia can be seen (arrows).

239

240

241 *Continuous Performance Task.* In a mixed linear effects model with medication status as a fixed effect

242 and participants as a random effect showed no significant effect on the continuous performance task

parameters (correct choice (Figure 4), errors and head movement (degrees of freedom: 11, t-value: 243 244 0.74, p-value: 0.47, estimate: 0.04 (SD:0.06))).

medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21265993; this version posted November 23, 2021. The copyright holder for this

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. **Responsivity of the striatal dopamine system to methylphenidate** – a within-subject I-123-B-**CIT-SPECT** study in adolescent males with ADHD



245 246 Figure 4: Comparison of correct choices in the continuous performance task on and off-MPH (p-value: 247 0.47).

248

249 Correlations between change of binding potential and clinical measures. The parent-rated severity of 250 internalizing and externalizing symptoms was evaluated at the time off-MPH using the CBCL 251 questionnaire. The severity of externalizing symptoms correlated with the change in binding potential 252 in the striatum due to MPH medication (Pearson r=0.68, p=0.01, Figure 5). This effect was driven by 253 the level of striatal binding potential off MPH (Pearson r=0.56, p=0.04) and not by the striatal binding 254 potential on MPH (Pearson r=-0.36, p=0.22). The severity of internalizing symptoms was neither 255 correlated with the change in striatal binding potential (Pearson r=0.47, p=0.11) nor the striatal binding 256 potential off (r=0.43, p=0.19) and on (r=-0.19, p=0.54) MPH.

257 To explore potential regional and hemisphere specific effects in the striatum linked to symptom 258 severity, the binding potentials of the left and right caudate nucleus and the putamen were estimated 259 separately. In a first step, we compared the correlation coefficients of the change in the binding 260 potential of the caudate nucleus (Pearson r=0.74, p=0.004) and the putamen (Pearson r=0.47, p=0.1) 261 with externalizing symptom severity, which differed significantly (z=-1.99, p=0.04). Between the 262 hemispheres, no relevant differences in correlation strength were found. The change of the binding 263 potential in the left putamen (r=0.63, p=0.02) had a stronger, but not significantly stronger (z=-1.79, 264 p=0.09), correlation with externalizing symptoms than the change of the binding potential of the right 265 putamen (r=0.17, p=0.58). The change of the binding potential of right caudate nucleus (Pearson r=0.7)

### medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21265993; this version posted November 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

#### preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Responsivity of the striatal dopamine system to methylphenidate – a within-subject I-123-ß-CIT-SPECT study in adolescent males with ADHD

showed only a slightly stronger correlation with the externalizing symptoms score than the correlation of the left caudate nucleus (Pearson r=0.65) with the externalizing symptoms score, which was not significant (z=0.5182, p-value=0.6043). The strongest correlation with symptom scores and change in binding potential was seen in the right caudate nucleus. Change in binding potential of the right caudate nucleus correlated with the externalizing (Pearson r=0.7, p=0.008) (Figure 5), but also with the internalizing (r=0.58, p=0.04) symptom severity of the patients at the time off-MPH.

- 272
- 273



Figure 5. Correlation of the externalizing symptoms score off MPH with the change of binding potential in the striatum (Pearson r=0.68, p=0.01) and in the right caudate nucleus (Pearson r=0.7, p=0.008).

277

Correlations of changes in CPT measures and binding potentials. Because the CPT was performed twice within subject on and off MPH, change scores could also be calculated in this case. The change in striatal binding potential did not correlate with a change in CPT outcomes (correct choices (Pearson r=-0.45, p=0.14), errors (Pearson r=0.34, p=0.28), reaction times (Pearson r=0.09, p=0.78), head movement (Pearson r=-0.42, p=0.19)).

283 In explorative analyses, there was a marginally non-significant correlation of the change in the binding 284 potential of the right caudate nucleus with the change in the correct responses in the CPT (Pearson r= 285 - 0.54, p=0.07). Because the change scores of the binding potentials and the CPT scores were calculated 286 off-on MPH, a better performance in the CPT under medication implies a decrease in the change score, 287 therefore the correlation of the change of the binding potential and the correct responses in the CPT is 288 negative (Figure 6). To test whether this effect was specific to the right caudate nucleus, the correlation 289 coefficients of the change in correct responses in the CPT and binding potentials in the right putamen 290 and left caudate nucleus were compared with those of the right caudate nucleus. There was a significant 291 difference in the strength of the correlation between the right caudate nucleus and the right putamen (z 292 = -2.5917, p-value = 0.009) and a marginal difference in the correlation strength between the left and 293 right caudate nucleus (z = 1.9124, p-value = 0.05). The change in binding potential in the right caudate 294 nucleus did not correlate with any other outcome change in the CPT (errors (Pearson r = 0.38, p = 0.23), 295 head movement (Pearson r=-0.31, p=0.36) and reaction time (Pearson r=0.1, p=0.75)). The change of 296 binding potential of the right (r=0.22, p=0.49) and left (r= -0.47, p=0.12) putamen, or the left caudate 297 nucleus (r= -0.32, p=0.32) did not correlate with the change of correct responses in the CPT.

Responsivity of the striatal dopamine system to methylphenidate – a within-subject I-123-ß-CIT-SPECT study in adolescent males with ADHD



Figure 6. Correlations between the change of the binding potentials in the striatum (Pearson r=-0.45, p=0.14) and the right caudate nucleus (Pearson r=-0.54, p=0.07) and the change of correct choices in

- 302 the continuous performance test.
- 303

299

## **CIT-SPECT** study in adolescent males with ADHD

#### Discussion 305

306 We present one of few within-subject studies assessing striatal DAT density in children and adolescents 307 with ADHD. Our results show that MPH administration leads to a significant decrease in DAT 308 availability. The severity of externalizing symptoms off-MPH correlated with the change in DAT. 309 Further explorative analyses indicated a correlation between change in DAT in the right caudate 310 nucleus and change in the correct choices in the CPT. Especially correlations with symptoms and CPT 311 thus add substantially to the small body of literature. Further, our study extends previous studies by the

312 type of design.

313 Our data corroborate the observation from previous studies that MPH on a group level leads to a 314 significant reduction of DAT binding (likely reflecting higher striatal DA levels). Despite this already 315 established finding in adults and adolescents (5, 13, 30), our study is the first to actually provide 316 evidence for a positive correlation between striatal DAT binding off-MPH and the severity of 317 externalizing symptoms off-MPH. Region-specific analyses showed a marginally non-significant 318 correlation between the decrease in DAT availability in the right caudate nucleus and the improvement 319 in performance on the CPT. To our knowledge, previous studies in children or adolescents have not 320 investigated this question (31, 32) or did not find significant correlations (24, 33). The study by Szobot 321 et al. recruited psychostimulant-naive patients with substance abuse disorder including cannabis, 322 cocaine and alcohol. Medication of MPH (1.2mg per kg body weight) for 3 weeks decreased core 323 ADHD symptoms and striatal DAT availability. However, neither naive DAT availability related to 324 clinical effect, nor were there correlations between changes in ADHD symptomatology and DAT 325 availability (24). The study by Akay et al. included under-age patients over a 2-month period to 326 evaluate the effects of MPH on striatal DAT availability and ADHD core symptomatology. Therapy 327 with MPH lead to reduced striatal DAT availability (and ADHD core symptomatology). In the latter 328 study, a subgroup comparison showed that the patients with significantly reduced ADHD core 329 symptomatology by MPH, also showed a greater decrease in DAT availability (16). However, all 330 patients included in our studies received long-term MPH treatment, which has been discussed to lead 331 to an upregulation of DAT in adaption to long-term MPH treatment (10).

332 Both of the previous studies used 99mTc-TRODAT-1 as radioligand to quantify active dopamine 333 transporters in the striatum, whereas our study used I-123-B-CIT as radioligand. In a study with 334 Parkinson's disease patients, I-123-B-CIT was found to be superior in sensitivity and specificity for 335 quantifying the functionality of dopaminergic synapses (34). Furthermore, both studies recruited only 336 psychostimulant-naive patients, whereas the patients in our study were all long-term treated with MPH 337 before study inclusion. This may have had an effect on the availability of DAT off-MPH (10, 12, 13). 338 Our study results are in line with meta-analytic evidence from genome-wide association studies for an 339 association between the genes encoding DAT (SLC6A3), Catechol-O-Methyltransferase (COMT) or 340 the dopamine receptor D4 (DRD4) and the clinical efficacy of MPH (35). MPH and amphetamines, 341 which both act mainly at DAT, are established as the most effective medication as first-line therapy 342 (4). A large number of cognitive neuroimaging studies have shown alterations in the dopaminergic 343 mesolimbic system, a neural circuit associated with motivated behaviors, reward learning and higher-344 order cognition (36-38). One hypothesis is that extracellular dopamine levels and tonic release of 345 dopamine are decreased in ADHD patients, resulting in increased stimulus-dependent phasic releases 346 of dopamine (potentially via presynaptic auto-receptors (39)). This impaired signal-to-noise ratio could 347 provide increased distractibility to external stimuli (40). Another hypothesis is that both phasic and 348 tonic release of dopamine is decreased in ADHD patients, which would explain why effects of 349 reinforcement are weakened in ADHD patients to motivate behavior (41-43). Indeed, increased DAT 350 availability could indicate lowered extracellular dopamine levels. In sum, our study is in line with

## **CIT-SPECT** study in adolescent males with ADHD

351 relatively lower DA levels (higher DAT) before treatment but cannot contribute to the question how 352 phasic DA release might be altered. However, also the factors contributing to decreased extracellular 353 dopamine levels are still matter of ongoing research. For example, an overactivity of the DAT itself, a 354 dysfunction of dopamine receptors or presynaptic autoreceptors are conceivable to play a role (44, 45). 355 These effects could also emerge as a result of aberrant glutamatergic and GABAergic influences over

356 the dopamine system (46).

357 The right caudate nucleus and its possible role in the pathophysiology of ADHD is already described 358 in other publications. A study attempted to measure tonic release and phasic dopamine release with a 359 D2 PET displacement measurement during a response inhibition task. They found that dopamine levels 360 of ADHD patients, specifically in the right caudate nucleus, were generally lower but higher during 361 the response inhibition task (putatively reflecting higher phasic release) as compared to healthy adults 362 (47). While these changes were also visible throughout the striatum, they were significant in the right 363 caudate nucleus (47). A larger PET study in adult ADHD patients also confirmed increased DAT 364 availability in the right caudate nucleus of ADHD patients, which could be indicative of lower tonic 365 dopamine levels (48). A meta-analysis comparing structural MRI images between ADHD patients and healthy controls showed that specifically the right caudate nucleus is one of the regions that differ most 366 367 in volume from controls in ADHD patients (49). A meta-analysis of 23 fMRI found a significant 368 difference between minor and adult ADHD patients exclusively in the right caudate nucleus. In this meta-analysis, activation in the right caudate nucleus was lower in minors than in adult ADHD patients 369 370 during response inhibition tasks (50). A randomized clinical trial using a Go/NoGo task during fMRI 371 to assess potential biomarkers for predicting clinical response to MPH showed increased baseline 372 activation in the right caudate nucleus in patients with a particularly good clinical response to MPH,

373 but only when considered in combination with response to atomoxetine (51).

374 One limitation of our study is that we provide intra-individual comparisons of pre-medicated patients 375 in absence of a healthy control group. Thus, we cannot determine the effects of chronic medication on 376 the status prior to installation of MPH in our participants. However, a meta-analysis on SPECT and 377 PET studies investigating DAT binding in ADHD compared to controls suggests that a history of 378 medication may lead to adaptation resulting in higher DAT binding (10). One may argue that in line 379 with the meta-analysis by Fusar-Poli et al. DAT binding in our sample has already been increased due 380 to chronic medication and that cessation of chronic MPH treatment may have further increased DAT 381 availability. This increase in DAT availability over 12 months of MPH therapy has already been 382 demonstrated in a prospective study (12). In line with this notion, secondary adaptation processes may 383 reverse or at least weaken the initial pharmacological effect of reducing DAT availability. This has 384 been suggested as an account of decreased efficacy of MPH treatment in the long run. Another 385 limitation of our study design was that no on-drug clinical evaluations were collected to examine the 386 clinical effect of MPH and correlate it with the changes in binding potentials. Only the continuous 387 performance test was performed on and off drug. Given our small sample size of 13 patients, our results 388 should be considered an exploratory analysis that requires replication with a larger sample also because 389 sample sizes are prone to substantially overestimate effect sizes (52). This needs to be emphasized in 390 particular because exploratory correlation analyses reported were not corrected for multiple 391 comparisons.

392 In summary, the results of our study support the importance of the DAT, specifically in the striatum, 393 in relation to responsivity to MPH. Our findings could inform future studies exploring individualized 394 prediction of the treatment efficacy of MPH in childhood and adolescent patients. This potential has 395 already been indicated by two other studies in adolescent (53) and adult (54) ADHD patients. Besides 396 the established nuclear imaging methods, it would also be beneficial to test proxy markers of DA, and 397 also monoamine function more generally, for example by making use of recently developed

# **CIT-SPECT** study in adolescent males with ADHD

- 398 quantitative MRI methods (55). In combination with specifically designed neurocognitive tests
- 399 targeting the interaction of cognition and motivation from a reinforcement learning perspective (56)
- 400 this could provide an in-depth understanding of inter-individual differences in the treatment response
- to MPH to enable more individualized treatments in the future. 401

402

403

405 Acknowledgements:

406 Funding. This study was supported by a grant from the Interdisciplinary Centre of Clinical Research 407 at the Medical Faculty of the University of Würzburg ("Untersuchungen des Dopamin-Transporters 408 mittels TC-99m-TRODAT-1-SPECT bei Jugendlichen mit ADHS") and by the German Research 409 Foundation (DFG) as part of KFO 125 "Attention Deficit/Hyperactivity Syndrome (ADHD): 410 Molecular Pathogenesis and Endophenotypes in the Course of Treatment", project number 5397423. 411 HCA is supported by a Clinician Scientist Program at the Interdisciplinary Centre of Clinical Research 412 at the Medical Faculty of the University of Würzburg. LD is supported by the IFB Adiposity Diseases, 413 Federal Ministry of Education and Research (BMBF), Germany, GN: 01EO150 and the German 414 Research Foundation (DFG) as part of the Collaborative Research Centre 265 "Losing and Regaining 415 Control over drug intake" (402170461, Project A02).

416 Author contribution. HCA statistically analyzed the data and drafted the manuscript under supervision 417 of LD. MR, SW, MG developed the study design, recruited patients and collected clinical data. AM 418 collected and analyzed the CPT data. RL, CR, AB, PH, NH, KN were involved in SPECT data 419 collection and analyzed SPECT binding potentials data. All authors read and revised the manuscript.

420

422

### 423 **References**

Franke B, Michelini G, Asherson P, Banaschewski T, Bilbow A, Buitelaar JK, et al. Live fast,
die young? A review on the developmental trajectories of ADHD across the lifespan. Eur
Neuropsychopharmacol. 2018;28(10):1059-88.

427 2. Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et
428 al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers. 2015;1:15020.

3. Biederman J, Petty CR, O'Connor KB, Hyder LL, Faraone SV. Predictors of persistence in girls
with attention deficit hyperactivity disorder: results from an 11-year controlled follow-up study. Acta
Psychiatr Scand. 2012;125(2):147-56.

4. Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative
efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children,
adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry.
2018;5(9):727-38.

Krause J, la Fougere C, Krause KH, Ackenheil M, Dresel SH. Influence of striatal dopamine
transporter availability on the response to methylphenidate in adult patients with ADHD. Eur Arch
Psychiatry Clin Neurosci. 2005;255(6):428-31.

439 6. Wender PH, Reimherr FW, Marchant BK, Sanford ME, Czajkowski LA, Tomb DA. A one year
440 trial of methylphenidate in the treatment of ADHD. J Atten Disord. 2011;15(1):36-45.

Cortese S, Kelly C, Chabernaud C, Proal E, Di Martino A, Milham MP, et al. Toward systems
neuroscience of ADHD: a meta-analysis of 55 fMRI studies. Am J Psychiatry. 2012;169(10):1038-55.

443 8. Arns M, Conners CK, Kraemer HC. A decade of EEG Theta/Beta Ratio Research in ADHD: a
444 meta-analysis. J Atten Disord. 2013;17(5):374-83.

445 9. Volkow ND, Fowler JS, Wang GJ. The addicted human brain viewed in the light of imaging
446 studies: brain circuits and treatment strategies. Neuropharmacology. 2004;47 Suppl 1:3-13.

447 10. Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U. Striatal dopamine transporter alterations
448 in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiatry.
449 2012;169(3):264-72.

450 11. Vaughan RA, Foster JD. Mechanisms of dopamine transporter regulation in normal and disease

451 states. Trends Pharmacol Sci. 2013;34(9):489-96.

452 12. Wang GJ, Volkow ND, Wigal T, Kollins SH, Newcorn JH, Telang F, et al. Long-term stimulant

453 treatment affects brain dopamine transporter level in patients with attention deficit hyperactive454 disorder. PloS one. 2013;8(5):e63023.

455 13. Volkow ND, Wang GJ, Tomasi D, Kollins SH, Wigal TL, Newcorn JH, et al. Methylphenidate-

456 elicited dopamine increases in ventral striatum are associated with long-term symptom improvement

457 in adults with attention deficit hyperactivity disorder. J Neurosci. 2012;32(3):841-9.

45814.Telzer EH. Dopaminergic reward sensitivity can promote adolescent health: A new perspective

on the mechanism of ventral striatum activation. Developmental Cognitive Neuroscience. 2016;17:57-67.

461 15. Galván A. Adolescent development of the reward system. Frontiers in Human Neuroscience.
462 2010;4(6).

463 16. Akay AP, Kaya G, Kose S, Yazıcıoğlu Ç E, Erkuran H, Güney SA, et al. Genetic imaging study
464 with [Tc-(99m)] TRODAT-1 SPECT in adolescents with ADHD using OROS-methylphenidate. Prog
465 Neuropsychopharmacol Biol Psychiatry. 2018;86:294-300.

466 17. Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, et al. Iodine-123-beta-CIT
467 and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and
468 Parkinson's patients. J Nucl Med. 1998;39(9):1500-8.

18. Neumeyer JL, Wang SY, Milius RA, Baldwin RM, Zea-Ponce Y, Hoffer PB, et al. [123I]-2
beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine
reuptake sites in brain. J Med Chem. 1991;34(10):3144-6.

- 472 19. Piepsz A, Hahn K, Roca I, Ciofetta G, Toth G, Gordon I, et al. A radiopharmaceuticals schedule
  473 for imaging in paediatrics. Paediatric Task Group European Association Nuclear Medicine. Eur J Nucl
  474 Med. 1990;17(3-4):127-9.
- 475 20. Nowak DJ, Eisner RL, Fajman WA. Distance-weighted backprojection: a SPECT
  476 reconstruction technique. Radiology. 1986;159(2):531-6.
- 477 21. Holmes CJ, Hoge R, Collins L, Woods R, Toga AW, Evans AC. Enhancement of MR images
  478 using registration for signal averaging. J Comput Assist Tomogr. 1998;22(2):324-33.

479 22. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the
480 in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol.
481 1984;15(3):217-27.

482 23. Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, et al. EANM
483 procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter
484 ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37(2):443-50.

Szobot CM, Shih MC, Schaefer T, Júnior N, Hoexter MQ, Fu YK, et al. Methylphenidate DAT
binding in adolescents with Attention-Deficit/ Hyperactivity Disorder comorbid with Substance Use
Disorder--a single photon emission computed tomography with [Tc(99m)]TRODAT-1 study.
Neuroimage. 2008;40(3):1195-201.

489 25. A.A. Rizzo JGB, T. Bowerly, C. Van Der Zaag, L. Humphrey, U. Neumann, C. Chua, C.
490 Kyriakakis, A. Van Rooyen, and D. Sisemore. The Virtual Classroom: A Virtual Reality Environment
491 for the Assessment and Rehabilitation of Attention Deficits. CyberPsychology & Behavior.
492 2000;3(3):483-99.

493 26. Mühlberger A, Jekel K, Probst T, Schecklmann M, Conzelmann A, Andreatta M, et al. The
494 Influence of Methylphenidate on Hyperactivity and Attention Deficits in Children With ADHD: A
495 Virtual Classroom Test. J Atten Disord. 2020;24(2):277-89.

496 27. Roessner V, Becker A, Rothenberger A, Rohde LA, Banaschewski T. A cross-cultural
497 comparison between samples of Brazilian and German children with ADHD/HD using the Child
498 Behavior Checklist. Eur Arch Psychiatry Clin Neurosci. 2007;257(6):352-9.

Klasen H, Woerner W, Wolke D, Meyer R, Overmeyer S, Kaschnitz W, et al. Comparing the
German versions of the Strengths and Difficulties Questionnaire (SDQ-Deu) and the Child Behavior
Checklist. Eur Child Adolesc Psychiatry. 2000;9(4):271-6.

502 29. Dunn OJ, & Clark, V. Correlation coefficients measured on the same individuals. 1969;64:366503 77.

30. Dresel S, Krause J, Krause KH, LaFougere C, Brinkbäumer K, Kung HF, et al. Attention deficit
hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after
methylphenidate treatment. Eur J Nucl Med. 2000;27(10):1518-24.

### CIT-SPECT study in adolescent males with ADHD

507 31. Feron FJ, Hendriksen JG, van Kroonenburgh MJ, Blom-Coenjaerts C, Kessels AG, Jolles J, et

- al. Dopamine transporter in attention-deficit hyperactivity disorder normalizes after cessation of
   methylphenidate. Pediatr Neurol. 2005;33(3):179-83.
- 510 32. Vles JS, Feron FJ, Hendriksen JG, Jolles J, van Kroonenburgh MJ, Weber WE. 511 Methylphenidate down-regulates the dopamine receptor and transporter system in children with 512 attention deficit hyperkinetic disorder (ADHD). Neuropediatrics. 2003;34(2):77-80.
- 513 33. Cheon KA, Ryu YH, Kim YK, Namkoong K, Kim CH, Lee JD. Dopamine transporter density 514 in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity 515 disorder. Eur J Nucl Med Mol Imaging. 2003;30(2):306-11.
- 516 34. Van Laere K, De Ceuninck L, Dom R, Van den Eynden J, Vanbilloen H, Cleynhens J, et al.
- 517 Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-
- 518 1. Eur J Nucl Med Mol Imaging. 2004;31(8):1119-27.
- 519 35. Myer NM, Boland JR, Faraone SV. Pharmacogenetics predictors of methylphenidate efficacy
  520 in childhood ADHD. Mol Psychiatry. 2018;23(9):1929-36.
- 521 36. Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet.
  522 2020;395(10222):450-62.
- 37. Posner J, Rauh V, Gruber A, Gat I, Wang Z, Peterson BS. Dissociable attentional and affective
  circuits in medication-naïve children with attention-deficit/hyperactivity disorder. Psychiatry Res.
  2013;213(1):24-30.
- 526 38. Cools R, D'Esposito M. Inverted-U-shaped dopamine actions on human working memory and
  527 cognitive control. Biol Psychiatry. 2011;69(12):e113-25.
- 528 39. Grace AA. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and
  529 depression. Nat Rev Neurosci. 2016;17(8):524-32.
- 530 40. Sikström S, Söderlund G. Stimulus-dependent dopamine release in attention-531 deficit/hyperactivity disorder. Psychol Rev. 2007;114(4):1047-75.
- 532 41. Frank MJ, Santamaria A, O'Reilly RC, Willcutt E. Testing computational models of dopamine
  533 and noradrenaline dysfunction in attention deficit/hyperactivity disorder. Neuropsychopharmacology.
  534 2007;32(7):1583-99.

535 42. Luman M, Oosterlaan J, Sergeant JA. The impact of reinforcement contingencies on AD/HD:

a review and theoretical appraisal. Clin Psychol Rev. 2005;25(2):183-213.

43. Luman M, Van Meel CS, Oosterlaan J, Sergeant JA, Geurts HM. Does reward frequency or
magnitude drive reinforcement-learning in attention-deficit/hyperactivity disorder? Psychiatry Res.

539 2009;168(3):222-9.

540 44. Olsen D, Wellner N, Kaas M, de Jong IEM, Sotty F, Didriksen M, et al. Altered dopaminergic

541 firing pattern and novelty response underlie ADHD-like behavior of SorCS2-deficient mice.

542 Translational psychiatry. 2021;11(1):74.

543 45. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The roles of dopamine and 544 noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol 545 Psychiatry. 2011;69(12):e145-57.

546 46. Gainetdinov RR, Mohn AR, Bohn LM, Caron MG. Glutamatergic modulation of hyperactivity
547 in mice lacking the dopamine transporter. Proceedings of the National Academy of Sciences.
548 2001;98(20):11047-54.

549 47. Badgaiyan RD, Sinha S, Sajjad M, Wack DS. Attenuated Tonic and Enhanced Phasic Release
550 of Dopamine in Attention Deficit Hyperactivity Disorder. PloS one. 2015;10(9):e0137326.

48. Spencer TJ, Biederman J, Madras BK, Dougherty DD, Bonab AA, Livni E, et al. Further
evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using
altropane. Biol Psychiatry. 2007;62(9):1059-61.

49. Valera EM, Faraone SV, Murray KE, Seidman LJ. Meta-analysis of structural imaging findings
in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61(12):1361-9.

556 50. Lei D, Du M, Wu M, Chen T, Huang X, Du X, et al. Functional MRI reveals different response
557 inhibition between adults and children with ADHD. Neuropsychology. 2015;29(6):874-81.

558 51. Schulz KP, Bedard AV, Fan J, Hildebrandt TB, Stein MA, Ivanov I, et al. Striatal Activation
559 Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine. J Am Acad Child
560 Adolesc Psychiatry. 2017;56(7):602-9 e2.

561 52. Bock M, Mohrs OK, Voigtlaender T, Kauczor HU, Semmler W. [MRI safety aspects and 562 artifacts of atrial septal defect and patent foramen ovale occluders at 1.5 tesla: a phantom study]. Rofo. 563 2006;178(3):272-7. medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21265993; this version posted November 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. All rights reserved. No reuse allowed without permission. CIT-SPECT study in adolescent males with ADHD

564 53. Ilgin N, Senol S, Gucuyener K, Gokcora N, Sener S. Is increased D2 receptor availability
565 associated with response to stimulant medication in ADHD. Dev Med Child Neurol. 2001;43(11):755566 60.

567 54. Krause J, la Fougere C, Krause KH, Ackenheil M, Dresel SH. Influence of striatal dopamine
568 transporter availability on the response to methylphenidate in adult patients with ADHD. European
569 Archives of Psychiatry and Clinical Neuroscience. 2005;255(6):428-31.

- 570 55. Tabelow K, Balteau E, Ashburner J, Callaghan MF, Draganski B, Helms G, et al. hMRI A
- toolbox for quantitative MRI in neuroscience and clinical research. Neuroimage. 2019;194:191-210.
- 572 56. Westbrook A, Bosch Rvd, Määttä JI, Hofmans L, Papadopetraki D, Cools R, et al. Dopamine 573 promotes cognitive effort by biasing the benefits versus costs of cognitive work. Science.
- 574 2020;367(6484):1362-6.
- 575
- 576
- 577